@article{ref1,
title="Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing",
journal="Alzheimer's and dementia",
year="2020",
author="Niznik, Joshua D. and Zhao, Xinhua and He, Meiqi and Aspinall, Sherrie L. and Hanlon, Joseph T. and Nace, David and Thorpe, Joshua M. and Thorpe, Carolyn T.",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="INTRODUCTION: We evaluated the impact of deprescribing acetylcholinesterase inhibitors (AChEIs) on aggressive behaviors and incident antipsychotic use in nursing home (NH) residents with severe dementia. <br><br>METHODS: We conducted a retrospective study of Medicare claims, Part D, Minimum Data Set for NH residents aged 65+ with severe dementia receiving AChEIs in 2016. Aggressive behaviors were measured using the aggressive behavior scale (ABS; n = 30,788). Incident antipsychotic prescriptions were evaluated among antipsychotic non-users (n = 25,188). Marginal structural models and inverse probability of treatment weights were used to evaluate associations of AChEI deprescribing and outcomes. <br><br>RESULTS: The severity of aggressive behaviors was low at baseline (mean ABS = 0.5) and was not associated with deprescribing AChEIs (0.002 increase in ABS, P =.90). Incident antipsychotic prescribing occurred in 5.1% of residents and was less likely with AChEI deprescribing (adjusted odds ratio = 0.52 [0.40-0.68], P <.001]). <br><br>DISCUSSION: Deprescribing AChEIs was not associated with a worsening of aggressive behaviors or incident antipsychotic prescriptions.<br><br>© 2020 the Alzheimer's Association.<p /> <p>Language: en</p>",
language="en",
issn="1552-5260",
doi="10.1002/alz.12054",
url="http://dx.doi.org/10.1002/alz.12054"
}